三种介入方法治疗动脉导管未闭的疗效评价

目的 :评价 Porstmann法、弹簧栓子法和 Amplatzer封堵器对动脉导管培养闭的治疗效果。方法 :3种方法共治疗动脉导管未闭 （PDA） 5 0例 ,其中 Porstm ann法 6例 ,弹簧栓子法 10例 ,Amplatzer封堵器 34例。所有患者在 PDA封堵后 10 m in重复主动脉造影观察有无残余分流 ;术后 2 4h、1月、6月和 12月行超声心电图检查 ,观察 PDA有无再通及残余分流。结果 :全组 5 0例 ,成功 49例。Porstm ann法有 1例由于鞘管不通过股动脉而失败。术后 10 min主动脉造影术 ,Amplatzer封堵器 4例有微 -少量残余分流。术术 2 4h超声心电图均无残余分流。随访 1～ 12个月 ,均未发现有残余分流和 PDA再通。结论 :经导管治疗 PDA是有效的非手术方法。Porstmann法已较少采用 ;直径 <3 m m的PDA首选弹簧栓子法 ;3～ 10 m m的 PDA采用 Am platzer封堵器治疗 ;直径 >10 m m者则应考虑手术治疗。     

Amplatzer封堵器治疗动脉导管未闭的即刻及短期疗效观察

目的:探讨应用Amplatzer封堵器治疗先天性动脉导管未闭(PDA)的疗效。方法:5例FPA患者,男2例,女3例,年龄6～27(平均18.40±7.23)岁;经临床、X线、超声心动图及造影证实为PDA。测量PDA最窄处内径,选择合适的输送鞘及封堵器,封堵缺损处。术后即刻听诊杂音及24小时后作超声心动图复查以评价疗效。结果:造影测量PDA最窄直径为4～7(5.20±1.16)mm,选择封堵器直径为8～18(12.80±3.25)mm.手术全部获得成功。4例杂音完全消失,复查超声心动图亦未见分流:1例存留不足2-级的收缩期杂音,术后超声心动图见微量残存分流,1月后复查残存分流消失。结论:Amplatzer封堵器治疗动脉导管未闭安全、有效,创伤小,可避免开胸治疗。     

Amplatzer封堵器介入治疗动脉导管未闭疗效分析

目的 评价Amplatzer封堵器介入治疗动脉导管未闭(PDA)的临床疗效。方法 对10例管型PDA患儿用Amplatzer PDA封堵器进行堵闭，2例窗型PDA用Amplatzer房间隔双伞封堵器堵闭。在透视下经6F输送器置入封堵器，术后10分钟，行右心导管检查及主动脉弓降部造影，术后24小时、1、3个月分别行彩色多普勒超声心动图、血常规及肝肾功能检查，评价治疗效果。结果 本组技术成功率为100％，患儿心脏双期连续性杂音均消失，术后10分钟主动脉弓降部造影显示少量残余分流2例，均为窗型PDA。术后24小时超声心动图示上述2例仍有微量分流。术后24小时、1、3个月行彩色多普勒超声心动图检查，均未发现残余分流、PDA再通及封堵器移位，血常规及肝肾功能检查均正常。2例有分流的患儿术后均出现急性溶血，经积极内科治疗后好转。其余10例无并发症发生。结论 应用Amplatzer封堵器介入治疗PDA安全有效，近中期疗效满意，远期疗效尚待进一步观察。对窗型PDA可试用Amplatzer房间隔封堵器堵闭。对术后发生急性溶血者可采用内科治疗。     

应用Amplatzer封堵器经导管治疗直径≥8mm动脉导管未闭的疗效评价

目的 :应用 Amplatzer封堵器经导管治疗直径≥ 8mm的大型动脉导管未闭 （PDA）并对其疗效进行评价。方法 :全组 5 0例 ,年龄 2 6 .4± 2 3.2 （4.0～ 6 0 .0 ）岁。 PDA最窄处直径为 10 .2± 2 .3（8.0～ 15 .0 ） mm。封堵 10 m in后行侧位降主动脉造影 ,术后 1d及 1月行超声心动图检查 ,观察有无残余分流及 PDA再通。结果 :47例 PDA采用Amplatzer PDA封堵器治疗 ,2例采用 Amplatzer ASD封堵器治疗 ,1例 PDA伴有阻力性肺动脉高压未行介入治疗。术后 10 min降主动脉造影显示 ,19例存在微～少量残余分流 ,30例封堵完全无残余分流。术后 2 4h、术后 1月超声心动图未见残余分流及再通。结论 :应用 Am platzer封堵器治疗直径≥ 8mm的大型动脉导管未闭是一种安全有效的介入方法。     

Amplatzer封堵器经导管治疗动脉导管未闭169例的随访结果

目的 :应用 Amplatzer封堵器经导管治疗动脉导管未闭 （PDA）术后随访。方法 :全组 16 9例。PDA最窄处直径为 4 .7± 3.8（2 .0～ 13.0 ） mm。封堵后 10 min行降主动脉造影 ,术后 2 4 h及 1,3,6月 ,1年行超声心动图检查随访。结果 :16 6例 PDA采用 Amplatzer PDA封堵器治疗 ,3例采用 Am platzer房间隔缺损封堵器治疗。 1例 PDA术中证实伴有阻力性肺动脉高压未行介入治疗。术后 10 m in降主动脉造影示 ,5 4例存在微～少量残余分流 ,114例封堵完全无残余分流。术后 2 4 h13例存在微～少量残余分流 ,余超声心动图未见残余分流及再通。 1例封堵术后 10h并发溶血 ,4 8h后行外科 PDA缝合术。术后 1月超声心动图检查 5例存在少量残余分流 ,术后 3月 4例存在少量残余分流 ,6月及 1年 3例存在少量残余分流 ,最后行 PFM弹簧圈治疗未再见残余分流。无并发症发生。结论 :应用 Am platzer封堵器治疗 PDA是一种安全有效的介入方法     

用Amplatzer封堵器介入治疗房间隔缺损及动脉导管未闭(附23例报告)

目的　探讨应用Amplatzer封堵器治疗先天性心脏病心房间隔缺损 (atrialseptaldefect,ASD)及动脉导管未闭 (patentductusarteriosus ,PDA)的方法并评价其疗效。方法　 2 3例患者 (ASD 19例 ,PDA 4例 )。所有病例均在X线透视、造影及食道超声心动图监视下经导管置入Amplatzer封堵器治疗ASD及PDA。结果　全组技术成功率 10 0 %。 2 3例患者术后 2 4h、1周行经胸超声心动图 (TTE)检查 ,有 2例存在残余分流 ,术后即刻完全封堵率 91 2 %。术后 6个月随访TTE检查示所有病例均封堵完全 ,无残余分流 ;X线检查全部显示肺血减少 ,心胸比例不同程度缩小。结论　经导管置入Amp latzer封堵器是治疗ASD和PDA的一种操作简便、技术成功率高、疗效可靠的介入方法。     

应用Amplatzer封堵器经导管治疗动脉导管未闭开胸术后再通的疗效评价

目的 :应用 Am platzer封堵器经导管治疗动脉导管未闭 （PDA）开胸术后再通并对其疗效进行评价。方法 :全组10例 ,年龄 11± 8（4～ 32 ）岁。PDA最窄处直径为 4± 4（2～ 13） mm。封堵后 10 m in行侧位降主动脉造影 ,术后 1d及 1月行超声心动图检查 ,观察有无残余分流及 PDA再通。结果 :9例 PDA采用 Am platzer PDA封堵器治疗 ,1例采用 Amplatzer房间隔缺损封堵器治疗。术后 10 m in降主动脉造影显示 ,3例存在微量～少量残余分流 ,7例封堵完全无残余分流。术后 2 4h、术后 1月超声心动图均未见残余分流及再通。结论 :应用 Amplatzer封堵器治疗动脉导管未闭外科术后再通是一种安全有效的介入方法。     

应用Amplatzer封堵器治疗动脉导管未闭

目的　采用Amplatzer封堵器经皮穿刺静脉治疗动脉导管未闭 ,并对其疗效、安全性及并发症进行评价。方法　 31例患者 ,年龄 0 8～ 38 0 (8 1± 6 0 )岁 ,体重 7 0～ 6 9 5 (2 7 7± 2 0 2 )kg。经静脉使用 6F传送器置入Amplatzer堵闭器 ,听诊无杂音后 10min行胸主动脉造影。术前、术后均行血流动力学测定 ,术后 2 4h、3个月、6个月行超声心动图及X线平片检查。结果　全组技术成功率10 0 %。术后即刻所有患者心前区双期连续性杂音消失 ,10min后胸主动脉造影示 2 9例完全堵闭(93 5 % ) ,仅 2例存在极少量残余分流 ,且 48h后超声心动图示该分流消失。动脉导管最窄径 1 5～8 2 (4 4± 1 7)mm ,透视时间 3 0～ 14 5 (6 7± 2 3)min。除 1例患者术后短暂胸部不适外均无任何并发症。随访 3～ 17(9 3± 3 7)个月未发生装置移位、再通或肺动脉狭窄。结论　应用Amplatzer方法经导管治疗动脉导管未闭安全简便 ,创伤小 ,适应证广 ,成功率高 ,疗效可靠 ,可用于新生儿 ,是目前治疗动脉导管未闭最理想的方法。     

国产封堵器介入治疗巨大动脉导管未闭的临床评价

目的应用国产封堵器经导管治疗巨大动脉导管未闭（PDA）并对其疗效进行评价。方法全组27（男8,女19）例,年龄6～54（24±15）岁,主动脉造影示PDA最窄径为13～28（16±4）mm。封堵后即刻和30min行侧位降主动脉造影,术后2d,1、3、6个月分别行超声心动图及X线平片检查。结果24例成功,3例PDA封堵后判断为有阻力性肺动脉高压,放弃治疗。成功的患者中,14例选用国产PDA封堵器,10例选用国产ASD封堵器。术后即刻降主动脉造影检查示,使用ASD封堵器中,有2例微量残余分流,5例少量残余分流,1例少～中量残余分流;PDA封堵器中,有4例微量残余分流,2例少量残余分流。术后30min,ASD封堵器4例微～少量残余分流,1例仍为少～中量残余分流;PDA封堵器仅2例微量残余分流。1例ASD封堵器治疗术后7h发生溶血,治疗72h溶血无减轻迹象,外科开胸取出封堵器并行PDA结扎术。术后2d,超声心动图示PDA封堵器1例微量残余分流,ASD封堵器5例微量残余分流。随访1～6个月,所有左心内径增大的患者均明显回缩,未发现残余分流和导管再通。结论应用国产封堵器经导管治疗直径≥13mm的PDA是一种安全有效地介入方法。     

经导管介入治疗婴幼儿大型动脉导管未闭临床疗效

目的 探讨应用导管介入治疗直径≥5 mm婴幼儿大型动脉导管未闭(patent ductus arteriosus,PDA)的临床疗效.方法 回顾性分析60例大型PDA(直径≥5 mm)患儿的临床资料,着重分析手术方法、临床疗效和随访结果.结果 56例PDA采用Amplatzer或国产先健动脉导管封堵器,3例采用膜部室间隔缺损封堵器,1例采用肌部室间隔缺损封堵器.封堵成功率为98.3%(59/60),术后1 d超声心动图显示15%(9/60)微量至少量残余分流,术后3月超声心动图复查未见残余分流;3例采用室间隔缺损封堵器患儿术后12月超声心动图示左肺动脉血流速度增快.结论 应用导管介入治疗直径≥5 mm婴幼儿大型PDA是安全、有效的方法.     

Patent ductus arteriosus equipment and technique. Amplatzer duct occluder: intermediate-term follow-up and technical considerations

Between May 1997 and June 2000, 69 patients, ages 0.1 to 34 years, underwent attempted anterograde transcatheter closure of a patent ductus arteriosus (PDA) using the Amplatzer Duct Occluder (ADO). The ADO is a cone-shaped, self-centering, and repositionable occluder made of nitinol wire mesh. A 5Fr to 7Fr sheath was used for the delivery of the device. The mean PDA diameter (at the pulmonary end) was 4.6 +/- 1.9 mm (range 1 mm-8.5 mm). Sixty-seven of the 69 patients had successful device placement. The mean ADO smallest diameter was 6.9 +/- 1.8 mm (range 4 mm-12 mm). Complete angiographic closure occurred in 62 (92.5%) of 67 patients (95% confidence interval, 88.22%-98.77%). In five patients, there was a trivial residual shunt immediately after the procedure. At 24 hours, color Doppler flow imaging revealed complete closure in all 67 (100%) patients. The unsuccessful attempts occurred in two patients with a small, 1-mm diameter native PDA and residual PDA after surgical occlusion. Fluoroscopy time was 7.6 +/- 1.8 minutes (4 min-18 min). No complications were observed. At a median follow-up of 1.5 years (range 0.25 to 3.2 years), all patients had complete closure without complications. We conclude that transcatheter closure using the ADO is a highly effective and safe treatment for most patients with PDA.     

Patent ductus arteriosus closure using the new Amplatzer Duct Occluder. Preliminary results and review of the literature.

BACKGROUND: Patent ductus arteriosus (PDA) is the second most common congenital heart disease. A large number of surgical and transcatheter techniques for the interruption or closure of PDA has been reported. The aim of this study was to assess the immediate and short-term results of transcatheter closure of PDA using the new, self-expandable, self-centering, and repositionable Amplatzer Duct Occluder device. METHODS: We attempted occlusion of PDA with the Amplatzer Duct Occluder in seven consecutive patients, one child and six adults, four females and three males, between September 1999 and January 30th 2000. All PDAs but one were approached from the femoral venous site; the Amplatzer Duct Occluder size was selected in order to be 2 mm larger than the duct's diameter at its narrowest site and the mean PDA diameter was 5.4+/-2.5 mm (range 3-9). All patients underwent physical examination, chest X-ray and echocardiography within 48 hours and on first and third month after PDA occlusion. RESULTS: Four patients had a megaphone type (type A), and three had an elongated, conical type (type E) PDA. Four patients had immediate, complete angiographic closure of the ductus 10 minutes after the procedure, one had a trace shunt and two had small shunts which all disappeared within 48 hours. The average fluoroscopy time and procedural time were 34.4+/-10.6 min (range 21-50) and 105+/-38.9 min (range 75-190) respectively. There were no complications at follow-up. CONCLUSIONS: Transcatheter closure of PDA using the new Amplatzer Duct Occluder is an easy and effective technique. Moreover it is safe even in the presence of wide PDAs.     

Retrograde transcatheter closure of ventricular septal defects in children using the Amplatzer Duct Occluder II

Objectives: To describe the technique and results of transcatheter closure of ventricular septal defects (VSDs) by a modified retrograde transarterial approach using the new Amplatzer Duct Occluder II (ADO II). Background: Transcatheter device closure of ventricular septal defects (VSDs) by antegrade method is well established, but a challenging procedure. We describe a retrograde technique that obviates the need for arteriovenous looping. Material and Methods: This is a prospective study from a single center. Between April 2009 and February 2010 13 children were identified for closure of various types of perimembranous and muscular VSDs using the ADO II device. All had met the criteria for surgical closure. Following left ventricular angiogram two were excluded as technically nonfeasible. The median age was 48 months (range 15–78). The median weight was 14 kg (range 7.5–20). The device was successfully deployed in the 11 selected children by the method described. The follow‐up evaluation included chest roentgenogram, ECG, and echocardiogram on day 1, at 6 weeks, at 3, 6, and 12 months. Results: The immediate and follow up complete closure rates were 73 and 82%, respectively. The median fluoroscopic time was 14 min (range 8.2–45). There were no procedure related complications. All patients were doing well at median follow up of 10 months; none showing any conduction abnormality. Conclusion: Transcatheter retrograde device closure of selected cases of Ventricular Septal Defects using the Amplatzer Duct Occluder II is simple and appears safe in the short term and can be completed within a short fluoroscopic time.© 2010 Wiley‐Liss, Inc.     

Safety of transcatheter patent ductus arteriosus closure in small weight infants

Background: Patent ductus arteriosus (PDA) is a frequent congenital heart disease. Its transcatheter closure has become the treatment of choice in children and adults. However, the device closure of PDA in children with low weight is still challenging with high rate of complications. The aim of this study was to report further experience with trancatheter closure of PDA using the Amplatzer Duct Occluder(ADO) for children weighing less or equal to 8 kg. Methods: Twenty‐two patients (5 male, 17 female) underwent transcatheter closure of a PDA using ADO at a median age of 10 months (range 4 to 26) and a median weight of 7 kg (range 4.3 to 8). Follow‐up evaluations were performed with Doppler echocardiography at 24h, and at 6 and 12 months. Results: The device was implanted successfully in all patients. The median fluoroscopy time was 17.25 min (range 10 to 29). Within 24h, color Doppler revealed complete closure in 15 patients (68%), the other patients had a small residual shunt. No deaths were associated with the procedure. Two patients had a slight aortic protrusion of the device without coarctation and in one patient the device encroached partially on the left pulmonary artery without significant acceleration on Doppler echocardiography. All patients were discharged home the next day. All patients completed the 6‐month follow‐up with complete closure in 18 patients (81%). At the last evaluation in all patients at any time, there has been documentation of complete PDA closure in 20 (91%) of 22 patients. Conclusion: In patients weighing less or equal to 8 kg, percutaneous closure of PDA using an ADO is a safe and effective procedure. (J Interven Cardiol 2012;25:391–394)     

Transcatheter occlusion of the patent ductus arteriosus in infants: Experimental testing of a new Amplatzer device

Objectives: This study assessed the feasibility and efficacy of implanting a new miniaturized nitinol device to occlude the patent ductus arteriosus (PDA) in a newborn porcine model. Background: Transcatheter device closure is the standard of care for PDA in older children and adults. Currently available technology is not designed for the newborn infant. Methods: The Amplatzer Duct Occluder II 0.5 is a new transcatheter Nitinol device without fabric designed to close the PDA with small aortic and pulmonary artery structures. The device was implanted in 8 infant pigs (average weight 2,400 g) after balloon dilation of PDA (average diameter 2.7 mm, average length 5.8 mm) with immediate, ～ 7, ～ 30, and ～ 90 day follow‐up by echocardiography, angiography, and final pathological examination. Half were implanted arterial, and half venous. Results: The device was successfully implanted in all animals. There was complete occlusion of the PDA in all cases without obstruction of the pulmonary arteries or aorta. There was complete late endothelialization without thrombus. The only complication was transection of a femoral artery accessed by cutdown. Conclusions: The success of this animal study confirms safety and feasibility of the Amplatzer Duct Occluder II 0.5 (now known as the ADO II AS) for use when the aorta and pulmonary arteries are small. Consideration can be given to transcatheter closure of the PDA in preterm and other small infants with this device. © 2011 Wiley Periodicals, Inc.     

动脉导管未闭合并重度肺动脉高压Amplatzer法封堵治疗的临床应用--12例初步报告

目的评价Amplatzer封堵器治疗动脉导管未闭(PDA)合并重度肺动脉高压(SPH)的初步疗效.方法对12例(女9例,男3例)PDA合并SPH患者实施封堵治疗.其中10例采用Amplatzer动脉导管未闭封堵器,2例采用Amplatzer房间隔缺损封堵器.结果全组12例PDA封堵器均放置成功.11例PDA封堵后30分至1小时肺动脉收缩压、肺动脉平均压均明显降低.1例封堵术后即刻肺动脉压无变化.术后36小时彩色多普勒估测肺动脉压明显下降,封堵术后30分降主动脉造影,无残余分流9例,微量残余分流2例,少量残余分流1例.全组术后24～48小时彩色多普勒检查,动脉水平左向右分流均完全消失.无重要并发症发生.随访1～24个月(平均8个月),患者症状改善,11例心脏缩小,无1例发生再通.结论采用Amplatzer法封堵治疗PDA合并SPH,近期疗效满意.     

Transcatheter closure of patent ductus arteriosus using the Amplatzer duct occluder: initial results and mid-term follow-up

INTRODUCTION AND OBJECTIVES: Transcatheter closure of patent ductus arteriosus is a well-established procedure. The aim of this study was to assess the initial and mid-term results of the treatment of PDA with the Amplatzer duct occluder. PATIENTS AND METHODS: From October 1999 to December 2001, 30 children underwent transcatheter closure of persistent ductus arteriosus at a mean SD age of 5 4.02 years (range: 3 months to 14 years) and weight of 20.3 10.3 kg (range: 4.5-45 kg). Infants under 10 kg weight made up 46% of total patients. A lateral view aortogram was made to determine the morphology of the ductus and select the size of the device. Occlusion was achieved using the anterograde venous approach. Follow-up evaluations were made with chest X-ray and echocardiogram at 24 hours and 1, 4 and 12 months after implantation. RESULTS: Twenty-eight patients (93.3%) immediately achieved complete occlusion, and on color Doppler examination the closure rate was 100% within 24 hours of implantation. There was no device embolization. In the follow-up, a 19-month-old patient developed a 20 mmHg gradient across the aortic arch. CONCLUSIONS: Patent ductus arteriosus can be easily occluded with the Amplatz Duct Occluder, which is effective and particularly useful in infants and children with relatively large PDA. Further experience and long-term follow-up are still needed to assess the safety of this device in smaller children.     

Device Closure of Patent Ductus Arteriosus in Marfan Patients: Safety and Effect on the Aortic Root Diameter

Objectives. There is little evidence in the medical literature about safety of PDA device closure and its effects on aortic root diameter in Marfan patients. We reported on nine Marfan patients whose ducts were occluded by coil or Amplatzer Duct Occluder. Patients and Interventions. Two patients had aneurismal type E ducts which were closed by a single coil, respectively. The others had conical ducts for which even Amplatzer occluder, stiff, or double coils were used. Results. No untoward consequence was found during a median follow up period of 18.5 months (range 3 months to 6.33 years). Two patients had small residual shunts. The observed change in the mean ratio of aortic root diameter to its estimated value was statistically insignificant in seven patients who had complete data on their aortic root diameter before PDA closure and during the follow up. Conclusions. We concluded that PDA device closure in Marfan patients is safe. Risk of residual shunt is higher even after closure of small ducts.     

Residual VSD Closure with an ADO II Device in an Infant

Postoperative residual ventricular septal defects (VSDs) are often percutaneously closed using septal occluder devices. However, their use is not advisable in small infants, because of poor outcome. We describe the successful device closure of a residual muscular VSD with an Amplatzer Duct Occluder II (ADO II) device in a child weighing 4.5 kg. It appears that ADO II may be the preferable device for the closure of moderate defects in infants and small children because of its lower profile and trackability.     

Percutaneous transcatheter closure of patent ductus arteriosus: Initial experience of Sohag University

ObjectivesInitial experience with transcatheter closure of patent ductus arteriosus (PDA) using different types of devices is reported in Sohag University Hospital. We evaluated the outcome, complications, and also assessed the need of surgical backup for such interventional procedures.MethodsFrom March 2011 to September 2012, 51 patients who underwent transcatheter closure of PDA, were retrospectively identified and studied. Aortic angiogram was performed to evaluate the size, position, and shape of the duct for appropriately choosing the occluder device type and size. A second aortic angiogram was performed 10 min after device deployment. Echocardiography was repeated at intervals of 24 h, then at 1, 3, and 6 months after the procedure to assess complications. The PDA was closed by Amplatzer Duct Occluder (ADO) in 40 patients, Nit occlude PFM coil in five patients, Amplatzer muscular VSD in two patients and Detachable Cook coil in four patients .ResultsOf 51 cases, one patient had left pulmonary artery embolization of ADO that required surgical intervention. The PDA was successfully closed in 98.04% of the study population without any residual PDA shunting. All the patients were alive. Infants made up 29% of the total patients. 45 patients were children and six patients were adults.ConclusionOur initial results show that transcatheter occlusion of PDA using different types of devices is safe and effective with good midterm outcome alternative to surgery. Complications occurred in those with unfavorable duct anatomy and presence of pulmonary hypertension. Surgical backup was not important for such interventional procedures.